Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Choroidal Melanoma: early-phase trial registry
2 of 4 indexed Choroidal Melanoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 2 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Choroidal Melanoma: 4 US clinical trials tracked, 2 recruiting.
Choroidal Melanoma is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Aura Biosciences, running 2 of these trials.
Enrollment posture brief
Registry condition choroidal-melanoma
OPEN 2 | RECR 50% | LATE 1 | EARLY 2 | RANK #4115 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Choroidal Melanoma lists 2 open slots (50% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Choroidal Melanoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Choroidal Melanoma is recruiting above its size-band peers.
2 of 4 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma
Aura Biosciences
NCT03941379
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
Aura Biosciences
NCT06007690
Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma
Massachusetts Eye and Ear Infirmary
NCT00765921
Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)
New England Retina Associates
NCT01251978
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Choroidal Melanoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Choroidal Melanoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Choroidal Melanoma page
4 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Choroidal Melanoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Aura Biosciences sponsors the most Choroidal Melanoma trials on record, review their full trial history before evaluating a specific study. See Aura Biosciences's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Choroidal Melanoma condition card totals 4 registered trials; most-linked intervention 0.5 mg Ranibizumab; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.